Zacks: Analysts Anticipate Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Will Announce Earnings of -$0.29 Per Share

Brokerages expect that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will announce earnings of ($0.29) per share for the current fiscal quarter, according to Zacks. Three analysts have made estimates for Oramed Pharmaceuticals’ earnings. The highest EPS estimate is ($0.24) and the lowest is ($0.34). Oramed Pharmaceuticals posted earnings of ($0.18) per share during the same quarter last year, which would indicate a negative year over year growth rate of 61.1%. The company is scheduled to issue its next quarterly earnings report on Wednesday, November 27th.

On average, analysts expect that Oramed Pharmaceuticals will report full year earnings of ($0.98) per share for the current year, with EPS estimates ranging from ($1.02) to ($0.92). For the next year, analysts expect that the business will post earnings of ($0.99) per share, with EPS estimates ranging from ($1.00) to ($0.98). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research analysts that follow Oramed Pharmaceuticals.

Separately, HC Wainwright restated a “buy” rating on shares of Oramed Pharmaceuticals in a report on Wednesday, June 19th.

In other Oramed Pharmaceuticals news, Director Leonard Sank acquired 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 16th. The stock was bought at an average price of $3.47 per share, for a total transaction of $69,400.00. Following the acquisition, the director now directly owns 315,482 shares in the company, valued at $1,094,722.54. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last 90 days, insiders have purchased 25,817 shares of company stock valued at $91,009. 27.70% of the stock is owned by company insiders.

A hedge fund recently raised its stake in Oramed Pharmaceuticals stock. BlackRock Inc. boosted its holdings in shares of Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) by 137.2% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 69,343 shares of the biotechnology company’s stock after acquiring an additional 40,114 shares during the quarter. BlackRock Inc. owned 0.40% of Oramed Pharmaceuticals worth $208,000 as of its most recent SEC filing. 6.18% of the stock is owned by institutional investors and hedge funds.

ORMP traded down $0.09 during trading hours on Friday, reaching $3.87. 46,245 shares of the company’s stock traded hands, compared to its average volume of 33,690. The company’s 50-day moving average price is $3.42. Oramed Pharmaceuticals has a 52-week low of $2.78 and a 52-week high of $5.89.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule for the treatment of diabetes; and ORMD-0901, an oral glucagon-like peptide-1 analog capsule for the treatment of type 2 diabetes.

Read More: Index Funds

Get a free copy of the Zacks research report on Oramed Pharmaceuticals (ORMP)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with's FREE daily email newsletter.